CM Life Sciences II Inc.
CMIIW
NASDAQ2.68
USD
+0.13
- -
CIK
0001837412
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eli Decatur Casdin
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 667 Madison Avenue New York City NY United States of America
- IPO Date
- Apr 15, 2021
- CIK
- 0001837412
- Similar Companies
- Business
- CM Life Sciences II Inc. (CMIIW) operates as a blank check company, or special purpose acquisition company (SPAC), whose warrants trade on Nasdaq under the ticker CMIIW; it focuses on effecting mergers, capital stock exchanges, asset acquisitions, or similar business combinations with one or more businesses in the fragmented life sciences sector, including life sciences tools, synthetic biology, and diagnostics. The company, sponsored by affiliates of Casdin Capital LLC and Corvex Management LP and led by CEO Eli Casdin and Chairman Keith Meister, was formed in 2020 and is headquartered in New York, New York; prior to any business combination, it holds no significant operations and maintains cash proceeds from its February 2021 initial public offering of $276 million in trust. In September 2021, CM Life Sciences II completed a reverse merger with SomaLogic Inc., a proteomics technology company offering AI-data driven platforms for protein biomarker discovery, measurement, and clinical applications, resulting in the combined entity trading as SomaLogic Inc. (SLGC); SomaLogic's proteomics business was subsequently merged into Standard BioTools Inc. in January 2024 in an all-stock transaction, with Standard BioTools now providing multi-omic solutions such as CyTOF mass cytometry systems, Hyperion imaging systems, and Biomark genomics platforms for research in cancer, immunology, and other areas.
CM Life Sciences II Inc. Announces Separate Trading of its Shares of Class A Common Stock and Warrants, on or about April 15, 2021